Clinical Trials (Low Dose Naltrexone) LDN Research Trust

Condition

Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone

Condition: MS, Multiple Sclerosis, Pain

Use of low-dose naltrexone in the management of chronic pain conditions A systematic review

Condition: Pain

No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study

Condition: Autoimmune, Endocrine, Thyroid

MS breakthrough: Cancer drug repairs damaged myelin nerve tissue in human trials first

Condition: MS, Multiple Sclerosis

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study

Condition: Opiod

Low dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia

Condition: Diabetes, Obesity

Naltrexone a potential therapeutic candidate for COVID-19

Condition: General

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management

Condition: Opiod, Pain, Substance Use

Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone

Condition: Autoimmune, MS, Multiple Sclerosis

Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review

Condition: Fibromyalgia, LDN Radio Show, Pain

Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review

Condition: Hailey Hailey, Hailey-Hailey, LDN Radio Show, Pemphigus

Low-Dose Naltrexone Reverses Facial Mechanical Allodynia in a Rat Model of Trigeminal Neuralgia

Condition: Neuropathy, Pain

Sjogren's Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports

Condition: Dry Eye, Pain, Sjogren's Syndrome

Synergistic PXT3003 Therapy Uncouples Neuromuscular Function From Dysmyelination in Male Charcot-Marie-Tooth Disease Type 1A (CMT1A) Rats

Condition: Charcot Marie Tooth, Charcot-Marie-Tooth

Low-dose Naltrexone Inhibits the Epithelial-Mesenchymal Transition of Cervical Cancer Cells in Vitro and Effects Indirectly on Tumor-Associated Macrophages in Vivo

Condition: Cancer

Efficacy of Low Dose Naltrexone in Psoriasis

Condition: Psoriasis

The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris; a randomized controlled clinical trial

Condition: Autoimmune, Lichen, Skin

The Benefits of Low Dose Naltrexone

Condition: Autoimmune, Crohn’s, Fibromyalgia, Irritable Bowel Syndrome, Lupus, Lupus Erythematosus, Lyme Disease, MS, Multiple Sclerosis, Pain, PCOS, Polycystic Ovary Syndrome, RA, Rheumatoid, Rheumatoid arthritis, RSD

Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Condition: Pain, Skin

Anticonvulsant Effects of Thalidomide on Pentylenetetrazole-Induced Seizure in Mice: A Role for Opioidergic and Nitrergic Transmissions

Condition: Opiod, Seizure

Effects of Acute and Repeated Treatment With Methocinnamox, a Mu Opioid Receptor Antagonist, on Fentanyl Self-Administration in Rhesus Monkeys

Condition: Opiod, Pain

129 Medication Assisted Treatment Protocol

Condition: Opiod, Pain

Low-dose Naltrexone Therapy for Psoriasis

Condition: Autoimmune, Skin, Psoriasis

Transition of Patients With Opioid Use Disorder From Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

Condition: Opiod, Pain

Naltrexone Hydrochloride 1.5-mg and 4.5-mg Capsules

Condition: Complex Regional Pain Syndrome, Fibromyalgia, Pain, Psoriasis

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.

Condition: Cancer, Carcinoma, Colon

Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills

Condition: Autoimmune, CFS, Chronic Fatigue Syndrome, Depression, Epilepsy, Fatigue, Fibromyalgia, IBD, Inflammatory Bowel Disease, ME, ME/CFS, Mental Health, MS, Multiple Sclerosis, Myalgic Encephalomyelitis, Opiod, Pain, RA, Rheumatoid, Rheumatoid arthritis

Low‐dose naltrexone in Hailey–Hailey disease: the importance of dosing

Condition: Hailey Hailey, Hailey-Hailey, Pemphigus, Skin

Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships [Online ahead of print]

Condition: Fibromyalgia

Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis

Low-dose Naltrexone as a Treatment for Chronic Fatigue Syndrome

Condition: Chronic Fatigue Syndrome

Low-Dose Naltrexone Reduces Symptoms in Stiff-Person Syndrome

Condition: Stiff Person

Improvement of Hailey-Hailey Disease With Low-Dose Naltrexone

Condition: Hailey-Hailey

The Lowdown on Low-Dose Naltrexone

Condition: Dermatitis, Hailey Hailey, Hailey-Hailey, Lichen, Pemphigus, Pruritus, Psoriasis, Skin

Opioid-induced Hypogonadism: Pathophysiology, Clinical and Therapeutics Review

Condition: Opiod

The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response

Condition: Cancer

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma

Condition: Cancer

Very Low Dose Naltrexone in Opioid Detoxification: A Double-Blind, Randomized Clinical Trial of Efficacy and Safety

Condition: Opiod

Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Condition: CFS, Fatigue, ME, ME/CFS

Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study

Condition: Depression, Epilepsy

Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial

Condition: Osteoporosis

Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients

Condition: Fatigue, ME, ME/CFS